Connect Biopharma reports new mechanism data for rademikibart drug

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced new mechanism of action data for its drug candidate rademikibart and outlined clinical development priorities for 2026, according to a company press release.

The clinical-stage biopharmaceutical company reported that rademikibart demonstrates enhanced binding affinity to the IL-4 receptor compared to dupilumab, creating a more stable complex. Laboratory experiments using human airway smooth muscle cells showed rademikibart provided substantially greater improvement in responsiveness to β-agonist treatment compared to dupilumab in the presence of IL-4/IL-13.

The company stated that rademikibart substantially reversed IL-13 induced hyporesponsiveness to β-agonist treatment, while dupilumab showed no rescue effect in human precision cut lung slice experiments.

Connect Biopharma initiated a Phase 1b clinical study evaluating intravenous administration of rademikibart, with topline results expected in the first quarter of 2026. The company reported that preliminary data from this ongoing study demonstrate increases in FEV1 significantly faster than observed with subcutaneous administration.

Recruitment continues for Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations in asthma and chronic obstructive pulmonary disease (COPD). The company expects to report topline data from both studies in mid-2026.

As of September 30, 2025, Connect Biopharma reported cash, cash equivalents and short-term investments of $54.8 million. The company stated this funding is sufficient to support operations into 2027 based on current operating plans.

Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha, designed to block IL-4 and IL-13 functions in treating inflammatory diseases including asthma and COPD.

You May Also Be Interested In

• Lowe's names five executive vice presidents effective Sept. 1
• Hewlett Packard Enterprise (HPE) Tops Q3 EPS by 19c; raises guidance
• Broadcom (AVGO) Tops Q3 EPS by 11c, Offers Guidance